Efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy or cetuximab in the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a meta-analysis.
- DOI
- 10.3389/fphar.2026.1675407
- Published
- 2026
- Container
- Frontiers in pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2026.1675407,
title = {Efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy or cetuximab in the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a meta-analysis.},
author = {Chen Z and Zhong Z and Liang W and Feng Q and Wu M and Lin L and Huang G and Tang X and Quan J and Wei J and Qin J},
year = {2026},
journal = {Frontiers in pharmacology},
doi = {10.3389/fphar.2026.1675407},
url = {https://doi.org/10.3389/fphar.2026.1675407}
}RIS
TY - JOUR TI - Efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy or cetuximab in the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a meta-analysis. AU - Chen Z AU - Zhong Z AU - Liang W AU - Feng Q AU - Wu M AU - Lin L AU - Huang G AU - Tang X AU - Quan J AU - Wei J AU - Qin J PY - 2026 JO - Frontiers in pharmacology DO - 10.3389/fphar.2026.1675407 UR - https://doi.org/10.3389/fphar.2026.1675407 ER -
APA
Z, C., Z, Z., W, L., Q, F., M, W., L, L., G, H., X, T., J, Q., J, W., & J, Q. (2026). Efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy or cetuximab in the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a meta-analysis.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1675407
Source records
- pubmed · retrieved 2026-09-26T22:36:25.415Z